Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | BACE1 | P56817 | 5/20 | 1.00 |
| ▸ | BCL2 | P10415 | 4/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | CNR2 | P34972 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicatechin Gallate SCHEMBL30977096 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL39046 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| (-)-Catechingallate SCHEMBL31181360 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| (-)-Catechingallate SCHEMBL4639342 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL39047 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL4639313 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL13014548 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL4545330 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL8426343 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL31297152 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087667-A1 | METHOD OF MODIFICATION OF WHEY PROTEIN AT ACIDIC PH BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION | ARLA FOODS AMBA (DK) | 2026-04-30 | — | — | WO | claimed |
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| EP-4697979-A1 | METHOD OF PRODUCING A MODIFIED PROTEIN COMPOSITION BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION | Arla Foods amba (DK) | 2026-02-25 | — | — | EP | claimed |
| EP-4340640-B1 | HIGH PROTEIN, MICELLAR CASEIN-CONTAINING NUTRITIONAL LIQUIDS ENRICHED WITH CATECHIN-COMPOUNDS AND METHOD OF PRODUCTION | ARLA FOODS AMBA (DK) | 2026-02-04 | — | — | EP | claimed |
| US-20250275566-A1 | HIGH PROTEIN, MICELLAR CASEIN-CONTAINING NUTRITIONAL LIQUIDS ENRICHED WITH CATECHIN-COMPOUNDS AND METHOD OF PRODUCTION | ARLA FOODS AMBA (DK) | 2025-09-04 | — | — | US | claimed |
| US-12364728-B2 | Composition for reducing body fat comprising green tea extract containing gallocatechin gallate as an active ingredient and manufacturing method thereof | AMOREPACIFIC CORPORATION (KR) | 2025-07-22 | — | — | US | claimed |
| WO-2025096874-A1 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250134853-A1 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2025-05-01 | — | — | US | claimed |
| US-12208128-B2 | Compositions and methods for treating traveler's diarrhea | ARTESA LLC (US) | 2025-01-28 | — | — | US | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| WO-2013184884-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORPORATION (US) | 2013-12-12 | — | — | WO | claimed |
| EP-2670392-A2 | CAROTENOID PARTICLES AND USES THEREOF | IP Science Limited (GB) | 2013-12-11 | — | — | EP | claimed |
| WO-2013090884-A1 | BRADYRHIZOBIUM STRAINS | Novozymes Biologicals Holdings A/S (DK) | 2013-06-20 | — | — | WO | claimed |
| WO-2012104576-A2 | CAROTENOID PARTICLES AND USES THEREOF | IP SCIENCE LIMITED (GB) | 2012-08-09 | — | — | WO | claimed |
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | claimed |
| CN-102014636-A | Methods of treating cardiovascular disorders associated with atherosclerosis | AMCOL INTERNATIONAL CORP | 2011-04-13 | — | — | CN | claimed |
| US-20090098254-A1 | Methods And Compositions For Improving Sensory And Shelf Life Characteristics Of Raw Meat Products | TYSON FOODS, INC. | 2009-04-16 | — | — | US | claimed |
| CN-1192772-C | Application of epigallic catechin 3-gallate in treating HPV infection | XINGLIN TRADITIONAL CHINESE ME (CN) | 2005-03-16 | — | — | CN | claimed |
| CN-1413117-A | Drugs, drinks or foods | TAKARA SHUZO CO (JP) | 2003-04-23 | — | — | CN | claimed |
| CN-1382437-A | Application of epigallic catechin 3-gallate in treating HPV infection | XINGLIN TRADITIONAL CHINESE ME (CN) | 2002-12-04 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134853-A1 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | GGT1, SPR, PON1 | DYRK1A 4402/4885BACE1 4538/4885BCL2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.